Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amplia Therapeutics ( (AU:ATX) ) just unveiled an announcement.
Amplia Therapeutics reported further clinical and operational progress for its lead FAK inhibitor narmafotinib in the March 2026 quarter, highlighted by mature data from the ACCENT trial in metastatic pancreatic cancer showing a median overall survival of 11.1 months, an objective response rate of 35.9% and five confirmed complete responses, alongside a favourable tolerability profile when combined with gemcitabine and Abraxane. The company advanced its Phase 3 readiness by completing GMP-standard large-scale production of approximately 13 kg of narmafotinib, refining plans for a registrational pancreatic cancer study ahead of an anticipated FDA meeting, generating preclinical data suggesting synergy with emerging kRAS inhibitors, managing adjustments to its AMPLICITY trial after chemotherapy-related toxicities, and strengthening its finance function with the appointment of experienced life sciences CFO Hamish George, all of which reinforce its positioning in the evolving pancreatic cancer treatment landscape.
Amplia’s latest trial results position narmafotinib as a promising adjunct to chemotherapy and potentially targeted therapies in metastatic pancreatic cancer, supporting future registrational pathways. Operational milestones in manufacturing scale-up, regulatory planning, and leadership changes underscore the company’s transition toward later-stage development and potential commercial partnering opportunities in oncology.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an ASX-listed biotechnology company based in Melbourne that is developing new drugs for the treatment of cancer and fibrosis, with a particular focus on metastatic pancreatic cancer. Its lead asset is narmafotinib, a best-in-class focal adhesion kinase (FAK) inhibitor being advanced in combination with standard chemotherapies and potentially targeted therapies to improve outcomes in hard-to-treat solid tumours.
Average Trading Volume: 4,450,086
Technical Sentiment Signal: Buy
Current Market Cap: A$84.66M
Learn more about ATX stock on TipRanks’ Stock Analysis page.